Annette Matthies as CBO at Elicio Therapeutics
Elicio Therapeutics, a longstanding client of Occam Global's, has strengthened its leadership team with the appointment of Annette Matthies, PhD, as Chief Business Officer. Elicio Therapeutics is advancing its ground-breaking Amphiphile technology across immunotherapy and vaccine platforms to develop therapies for cancer and infectious disease.
Annette, trained as an immunologist and broadly experienced across therapeutic areas including oncology, will spearhead Elicio's business and corporate development initiatives with a particularly strong focus on partnership opportunities in 2021. Most recently, Annette served as VP of Corporate Development at eFFECTOR Therapeutics. Prior to that, she was an integral member of the corporate development teams of Receptos, acquired by Celgene for $7.2B, and Facet Biotech, acquired by Abbott Laboratories for $450M.
Previously, Occam placed Christopher Haqq MD/PhD as EVP, Head of R&D and Chief Medical Officer. More recently, Occam recruited Daphne Karydas to join Elicio's Board of Directors.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.